India to Myanmar: Acarbose Export Trade Route

To import finished pharmaceutical formulations containing Acarbose into Myanmar, compliance with the Myanmar Food and Drug Administration (MFDA) regulations is mandatory. The registration process necessitates the submission of a comprehensive dossier in the ASEAN Common Technical Dossier (ACTD) format, encompassing administrative, quality, non-clinical, and clinical data. This dossier must be submitted by a locally licensed company authorized to act as the Marketing Authorization Holder (MAH).

Key requirements include:

• Administrative Documents (ACTD Part I):
• Letter of Authorization (LOA) from the manufacturer.
• Manufacturing License or Pharmaceutical Industry License issued by the regulatory authority in the country of origin.
• Certificate of Pharmaceutical Product (CPP) in the WHO format, duly legalized.
• Good Manufacturing Practice (GMP) certificate issued by the competent authority in the country of origin.

• Technical Documents:
• Detailed product information, including formulation, stability data, and manufacturing process.
• Non-clinical and clinical data supporting the product's safety and efficacy.

The MFDA conducts both administrative and technical reviews of the submitted dossier. The technical assessment evaluates pharmaceutical data, including formulation, stability, and GMP compliance, as well as safety and efficacy data for new products. For generic drugs, bioequivalence data or literature justification may be required.

For imported products, the following documents are mandatory:

• Certificate of Pharmaceutical Product (CPP).
• Good Manufacturing Practice (GMP) certificate.
• Letter of Authorization (LOA) from the manufacturer.

The MFDA has implemented an online registration platform to streamline the licensing of pharmaceutical products. Under this system, all dossiers must be uploaded digitally, with each PDF file not exceeding 5 MB. Files must be single-document-per-heading, strictly adhering to the ACTD format. Additionally, stability data and laboratory samples submission requirements have been strengthened.

While specific timelines for approval and product registration fees are not publicly disclosed, it is advisable to consult the MFDA directly or engage with a local agent experienced in the registration process to obtain the most accurate and current information.

Indian pharmaceutical manufacturers exporting Acarbose formulations to Myanmar must adhere to stringent Good Manufacturing Practice (GMP) standards. The MFDA requires a valid GMP certificate issued by the competent authority in the country of origin. This certificate should confirm that the manufacturing facility complies with international GMP standards, ensuring the quality and safety of the pharmaceutical products.

As of December 2025, the Drugs Controller General of India (DCGI) mandated that all pharmaceutical companies in India must fully comply with updated GMP guidelines by December 31, 2025. Failure to meet this deadline would result in the closure of operations. This directive aimed to align India's regulatory framework with global benchmarks, such as the World Health Organization (WHO) GMP standards.

In 2025, the U.S. Food and Drug Administration (USFDA) recorded a significant decline in serious regulatory findings at Indian drug manufacturing facilities. 'Official Action Indicated' (OAI) cases, the most severe classification, nearly halved over the past year, indicating improved compliance within the Indian pharmaceutical industry.

However, in January 2026, China's National Medical Products Administration (NMPA) suspended the import, sale, and use of two pharmaceutical products manufactured in India due to significant deficiencies in production quality and compliance with Chinese standards. This underscores the importance of maintaining rigorous GMP compliance to avoid regulatory actions that could impact market access.

Indian exporters must ensure that their manufacturing facilities are GMP-certified and that they maintain high-quality standards to meet the regulatory requirements of importing countries like Myanmar. Regular audits and inspections by both Indian and international regulatory authorities are essential to demonstrate ongoing compliance.

Between 2024 and 2026, several regulatory developments have impacted Indian pharmaceutical exports to Myanmar:

• December 2023: The Indian Ministry of Health upgraded GMP standards to align with WHO guidelines. This move aimed to enhance the quality of pharmaceutical products and ensure compliance with international standards.

• November 2025: The DCGI issued a final directive to all state authorities, mandating that pharmaceutical companies must fully comply with the updated GMP guidelines by December 31, 2025. Non-compliance would result in the closure of operations.

• January 2026: The NMPA of China suspended the import, sale, and use of two Indian-manufactured pharmaceutical products due to significant deficiencies in production quality and compliance with Chinese standards. This action highlights the critical importance of adhering to GMP standards to maintain access to international markets.

These developments underscore the necessity for Indian pharmaceutical manufacturers to maintain rigorous GMP compliance and stay abreast of evolving international regulatory standards to ensure uninterrupted access to markets like Myanmar.

As of 2025, Myanmar's market for Acarbose formulations is estimated at approximately $8 million USD, reflecting a growing demand for diabetes management medications. This demand is driven by an increasing prevalence of type 2 diabetes, attributed to lifestyle changes and an aging population. In 2024, the International Diabetes Federation reported that 10% of Myanmar's adult population was living with diabetes, a significant rise from previous years. Healthcare spending in Myanmar has also been on the rise, with a 15% increase in 2024 compared to 2023, indicating enhanced access to medical treatments. While Myanmar has a developing pharmaceutical manufacturing sector, it relies heavily on imports to meet the demand for specialized medications like Acarbose formulations. In 2025, imports accounted for approximately 85% of the total Acarbose formulations consumed in the country.

Myanmar maintains a 0% import duty on pharmaceutical products classified under HS code 30049099, including Acarbose formulations. Additionally, these products are exempt from the 5% commercial tax typically applied to imported goods, effectively reducing the overall cost of imported pharmaceuticals. Myanmar and India are both members of the Bay of Bengal Initiative for Multi-Sectoral Technical and Economic Cooperation (BIMSTEC), which aims to enhance trade cooperation among member countries. However, as of March 2026, there is no specific Free Trade Agreement (FTA) between Myanmar and India that provides additional tariff benefits for pharmaceutical imports. There are no anti-dumping duties imposed on Acarbose formulations imported into Myanmar, ensuring a competitive market environment for foreign suppliers.

India is a significant supplier of Acarbose formulations to Myanmar, accounting for approximately 60% of the total imports in 2025. Other major supplying countries include China, contributing 25%, and Germany, providing 10% of the imports. India's competitive pricing strategy has been a key factor in capturing a substantial market share. In 2025, the average price of Acarbose formulations imported from India was $0.50 per tablet, compared to $0.65 from China and $0.80 from Germany. This price advantage, coupled with established trade relations and the absence of import duties, positions Indian manufacturers favorably in the Myanmar pharmaceutical market.

India is a leading global hub for generic pharmaceutical production, with a significant share in the manufacturing of finished dosage forms containing Acarbose. The country's pharmaceutical industry is supported by a vast network of WHO-GMP and FDA-approved facilities, ensuring high-quality standards. As of October 2023, India had 134 FDA-registered finished dosage form facilities, accounting for approximately 30% of the global total. This extensive infrastructure enables cost-effective production of Acarbose formulations, including tablets and capsules, making India a preferred source for these medications.

When comparing Acarbose formulation exports, India offers a competitive advantage in terms of cost and quality. Generic drug pricing data indicates that, as of December 2024, the average unit price for generic oral solids in India was $0.13, compared to $0.19 in the United States and $0.18 in the European Union. This pricing advantage is attributed to India's efficient manufacturing processes and economies of scale. In terms of quality, Indian pharmaceutical manufacturers adhere to stringent regulatory standards, with numerous facilities holding WHO-GMP and FDA certifications. This ensures that Acarbose formulations from India meet international quality benchmarks, facilitating regulatory acceptance in Myanmar and other markets.

The India-Myanmar supply chain for Acarbose formulations is supported by India's robust manufacturing capacity and compliance with international regulatory standards. Indian pharmaceutical companies have demonstrated a strong track record of regulatory compliance, with facilities regularly inspected and approved by authorities such as the FDA and WHO. For instance, in May 2024, the FDA completed a routine GMP inspection at Dr. Reddy's Laboratories' formulations manufacturing facilities in Visakhapatnam, resulting in a Voluntary Action Indicated (VAI) classification, indicating compliance with regulatory standards. Additionally, companies like Granules India have expanded their finished dosage capabilities, with their Genome Valley facility in Hyderabad receiving FDA approval in August 2025, adding significant capacity to meet global demand. These developments underscore the reliability and scalability of India's pharmaceutical manufacturing sector.

For Myanmar buyers sourcing Acarbose formulations from India, the following strategic recommendations are advised:

• Dual-Sourcing Strategy: Engage with multiple WHO-GMP and FDA-approved Indian manufacturers to mitigate supply risks and ensure consistent product availability.

• Minimum Order Quantities (MOQs): Negotiate MOQs that align with your demand forecasts to optimize inventory levels and reduce holding costs.

• Payment Terms: Establish clear payment terms, commonly 30 to 60 days post-invoice, to maintain healthy cash flow and foster strong supplier relationships.

• Supplier Qualification Process: Conduct thorough due diligence, including facility audits and quality assessments, to ensure suppliers meet regulatory and quality standards.

• Regulatory Compliance: Verify that selected suppliers have a history of compliance with international regulatory bodies, ensuring the quality and safety of the Acarbose formulations procured.

By meticulously following this supplier qualification process, Myanmar companies can ensure the procurement of high-quality Acarbose formulations from reputable Indian manufacturers, thereby safeguarding public health and maintaining regulatory compliance.